Skip to main content
Top
Published in: Journal of Translational Medicine 1/2017

Open Access 01-12-2017 | Research

Partnering with patients in translational oncology research: ethical approach

Authors: Marie-France Mamzer, Nathalie Duchange, Sylviane Darquy, Patrice Marvanne, Claude Rambaud, Giovanna Marsico, Catherine Cerisey, Florian Scotté, Anita Burgun, Cécile Badoual, Pierre Laurent-Puig, Christian Hervé

Published in: Journal of Translational Medicine | Issue 1/2017

Login to get access

Abstract

Background

The research program CARPEM (cancer research and personalized medicine) brings together the expertise of researchers and hospital-based oncologists to develop translational research in the context of personalized or “precision” medicine for cancer. There is recognition that patient involvement can help to take into account their needs and priorities in the development of this emerging practice but there is currently no consensus about how this can be achieved. In this study, we developed an empirical ethical research action aiming to improve patient representatives’ involvement in the development of the translational research program together with health professionals. The aim is to promote common understanding and sharing of knowledge between all parties and to establish a long-term partnership integrating patient’s expectations.

Methods

Two distinct committees were settled in CARPEM: an “Expert Committee”, gathering healthcare and research professionals, and a “Patient Committee”, gathering patients and patient representatives. A multidisciplinary team trained in medical ethics research ensured communication between the two committees as well as analysis of discussions, minutes and outputs from all stakeholders.

Results

The results highlight the efficiency of the transfer of knowledge between interested parties. Patient representatives and professionals were able to identify new ethical challenges and co-elaborate new procedures to gather information and consent forms for adapting to practices and recommendations developed during the process. Moreover, included patient representatives became full partners and participated in the transfer of knowledge to the public via conferences and publications.

Conclusions

Empirical ethical research based on a patient-centered approach could help in establishing a fair model for coordination and support actions during cancer research, striking a balance between the regulatory framework, researcher needs and patient expectations. Our approach addresses the concept of translational ethics as a way to handle the main remaining gap between combining care and research activities in the medical pathway and the existing framework.
Literature
1.
go back to reference Carneiro BA, Costa R, Taxter T, Chandra S, Chae YK, Cristofanilli M, et al. Is personalized medicine here? Oncology. 2016;30(293–303):307. Carneiro BA, Costa R, Taxter T, Chandra S, Chae YK, Cristofanilli M, et al. Is personalized medicine here? Oncology. 2016;30(293–303):307.
3.
go back to reference Duffy MJ, Sturgeon CM, Sölétormos G, Barak V, Molina R, Hayes DF, et al. Validation of new cancer biomarkers: a position statement from the european group on tumor markers. Clin Chem. 2015;61:809–20.CrossRefPubMed Duffy MJ, Sturgeon CM, Sölétormos G, Barak V, Molina R, Hayes DF, et al. Validation of new cancer biomarkers: a position statement from the european group on tumor markers. Clin Chem. 2015;61:809–20.CrossRefPubMed
4.
go back to reference Jameson JL, Longo DL. Precision medicine—personalized, problematic, and promising. N Engl J Med. 2015;372:2229–34.CrossRefPubMed Jameson JL, Longo DL. Precision medicine—personalized, problematic, and promising. N Engl J Med. 2015;372:2229–34.CrossRefPubMed
5.
go back to reference McDermott U, Downing JR, Stratton MR. Genomics and the continuum of cancer care. N Engl J Med. 2011;364:340–50.CrossRefPubMed McDermott U, Downing JR, Stratton MR. Genomics and the continuum of cancer care. N Engl J Med. 2011;364:340–50.CrossRefPubMed
6.
go back to reference Waldman SA, Terzic A. Clinical and translational science: from bench-bedside to global village. Clin Transl Sci. 2010;3:254–7.CrossRefPubMed Waldman SA, Terzic A. Clinical and translational science: from bench-bedside to global village. Clin Transl Sci. 2010;3:254–7.CrossRefPubMed
7.
go back to reference Hostiuc S, Moldoveanu A, Dascălu M-I, Unnthorsson R, Jóhannesson ÓI, Marcus I. Translational research-the need of a new bioethics approach. J Transl Med. 2016;14:16.CrossRefPubMedPubMedCentral Hostiuc S, Moldoveanu A, Dascălu M-I, Unnthorsson R, Jóhannesson ÓI, Marcus I. Translational research-the need of a new bioethics approach. J Transl Med. 2016;14:16.CrossRefPubMedPubMedCentral
8.
go back to reference Artene S-A, Ciurea ME, Purcaru SO, Tache DE, Tataranu LG, Lupu M, et al. Biobanking in a constantly developing medical world. Sci World J. 2013;2013:343275.CrossRef Artene S-A, Ciurea ME, Purcaru SO, Tache DE, Tataranu LG, Lupu M, et al. Biobanking in a constantly developing medical world. Sci World J. 2013;2013:343275.CrossRef
9.
go back to reference Siu LL, Lawler M, Haussler D, Knoppers BM, Lewin J, Vis DJ, et al. Facilitating a culture of responsible and effective sharing of cancer genome data. Nat Med. 2016;22:464–71.CrossRefPubMedPubMedCentral Siu LL, Lawler M, Haussler D, Knoppers BM, Lewin J, Vis DJ, et al. Facilitating a culture of responsible and effective sharing of cancer genome data. Nat Med. 2016;22:464–71.CrossRefPubMedPubMedCentral
10.
go back to reference Kagarise MJ, Sheldon GF. Translational ethics: a perspective for the new millennium. Arch Surg. 2000;135:39–45.CrossRefPubMed Kagarise MJ, Sheldon GF. Translational ethics: a perspective for the new millennium. Arch Surg. 2000;135:39–45.CrossRefPubMed
11.
go back to reference Wolf SM, Burke W, Koenig BA. Mapping the ethics of translational genomics: situating return of results and navigating the research-clinical divide. J Law Med Ethics. 2015;43:486–501.PubMedPubMedCentral Wolf SM, Burke W, Koenig BA. Mapping the ethics of translational genomics: situating return of results and navigating the research-clinical divide. J Law Med Ethics. 2015;43:486–501.PubMedPubMedCentral
12.
go back to reference Cribb A. Translational ethics? The theory–practice gap in medical ethics. J Med Ethics. 2010;36:207–10.CrossRefPubMed Cribb A. Translational ethics? The theory–practice gap in medical ethics. J Med Ethics. 2010;36:207–10.CrossRefPubMed
13.
go back to reference Nicol D, Bubela T, Chalmers D, Charbonneau J, Critchley C, Dickinson J, et al. Precision medicine: drowning in a regulatory soup? J Law Biosci. 2016;3:281–303.CrossRef Nicol D, Bubela T, Chalmers D, Charbonneau J, Critchley C, Dickinson J, et al. Precision medicine: drowning in a regulatory soup? J Law Biosci. 2016;3:281–303.CrossRef
14.
go back to reference Joly Y, Saulnier KM, Osien G, Knoppers BM. The ethical framing of personalized medicine. The ethical framing of personalized medicine. Curr Opin Allergy Clin Immunol. 2014;14:404–8.CrossRefPubMed Joly Y, Saulnier KM, Osien G, Knoppers BM. The ethical framing of personalized medicine. The ethical framing of personalized medicine. Curr Opin Allergy Clin Immunol. 2014;14:404–8.CrossRefPubMed
15.
go back to reference Rance B, Canuel V, Countouris H, Laurent-Puig P, Burgun A. Integrating heterogeneous biomedical data for cancer research: the CARPEM infrastructure. Appl Clin Inform. 2016;7:260–74.CrossRefPubMedPubMedCentral Rance B, Canuel V, Countouris H, Laurent-Puig P, Burgun A. Integrating heterogeneous biomedical data for cancer research: the CARPEM infrastructure. Appl Clin Inform. 2016;7:260–74.CrossRefPubMedPubMedCentral
16.
go back to reference Taieb J, Zaanan A, Le Malicot K, Julié C, Blons H, Mineur L, et al. Prognostic effect of BRAF and KRAS mutations in patients with stage III colon cancer treated with leucovorin, fluorouracil, and oxaliplatin with or without cetuximab: a post hoc analysis of the PETACC-8 trial. JAMA Oncol. 2016;2:1–11.CrossRef Taieb J, Zaanan A, Le Malicot K, Julié C, Blons H, Mineur L, et al. Prognostic effect of BRAF and KRAS mutations in patients with stage III colon cancer treated with leucovorin, fluorouracil, and oxaliplatin with or without cetuximab: a post hoc analysis of the PETACC-8 trial. JAMA Oncol. 2016;2:1–11.CrossRef
17.
go back to reference Becht E, de Reyniès A, Giraldo NA, Pilati C, Buttard B, Lacroix L, et al. Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy. Clin Cancer Res. 2016;22:4057–66.CrossRefPubMed Becht E, de Reyniès A, Giraldo NA, Pilati C, Buttard B, Lacroix L, et al. Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy. Clin Cancer Res. 2016;22:4057–66.CrossRefPubMed
19.
go back to reference McCormick JB, Sharp RR, Ottenberg AL, Reider CR, Taylor HA, Wilfond BS. The establishment of research ethics consultation services (RECS): an emerging research resource. Clin Transl Sci. 2013;6:40–4.CrossRefPubMed McCormick JB, Sharp RR, Ottenberg AL, Reider CR, Taylor HA, Wilfond BS. The establishment of research ethics consultation services (RECS): an emerging research resource. Clin Transl Sci. 2013;6:40–4.CrossRefPubMed
20.
go back to reference Sharp RR, Taylor HA, Brinich MA, Boyle MM, Cho M, Coors M, et al. Research ethics consultation: ethical and professional practice challenges and recommendations. Acad Med. 2015;90:615–20.CrossRefPubMedPubMedCentral Sharp RR, Taylor HA, Brinich MA, Boyle MM, Cho M, Coors M, et al. Research ethics consultation: ethical and professional practice challenges and recommendations. Acad Med. 2015;90:615–20.CrossRefPubMedPubMedCentral
21.
go back to reference Canuel V, Rance B, Avillach P, Degoulet P, Burgun A. Translational research platforms integrating clinical and omics data: a review of publicly available solutions. Br Bioinform. 2015;16:280–90.CrossRef Canuel V, Rance B, Avillach P, Degoulet P, Burgun A. Translational research platforms integrating clinical and omics data: a review of publicly available solutions. Br Bioinform. 2015;16:280–90.CrossRef
22.
go back to reference Burgun A, Jannot A-S, Rance B, Mamzer M-F. Sharing patient data for research: organizational and ethical aspects. JEMEP. 2016;2(3):435–41. Burgun A, Jannot A-S, Rance B, Mamzer M-F. Sharing patient data for research: organizational and ethical aspects. JEMEP. 2016;2(3):435–41.
23.
go back to reference Marvanne P, Rambaud C, Vergely C. La médecine prédictive ou personnalisée: prévoir les conséquences médicales, sociales et sociétales. In: Les nouveaux paradigmes de la médecine personnalisée ou médecine de précision. Paris: Dalloz Ed; 2014. p. 201–10. Marvanne P, Rambaud C, Vergely C. La médecine prédictive ou personnalisée: prévoir les conséquences médicales, sociales et sociétales. In: Les nouveaux paradigmes de la médecine personnalisée ou médecine de précision. Paris: Dalloz Ed; 2014. p. 201–10.
24.
go back to reference Master Z, Nelson E, Murdoch B, Caulfield T. Biobanks, consent and claims of consensus. Nat Methods. 2012;9:885–8.CrossRefPubMed Master Z, Nelson E, Murdoch B, Caulfield T. Biobanks, consent and claims of consensus. Nat Methods. 2012;9:885–8.CrossRefPubMed
25.
go back to reference Hansson MG, Dillner J, Bartram CR, Carlson JA, Helgesson G. Should donors be allowed to give broad consent to future biobank research? Lancet Oncol. 2006;7:266–9.CrossRefPubMed Hansson MG, Dillner J, Bartram CR, Carlson JA, Helgesson G. Should donors be allowed to give broad consent to future biobank research? Lancet Oncol. 2006;7:266–9.CrossRefPubMed
26.
go back to reference Leroy P, Mamzer-Bruneel M-F, Hervé C, Scotté F. Une étude des conditions de recueil des consentements : quels enseignements ? In: Les nouveaux paradigmes de la médecine personnalisée ou médecine de précision. Paris: Dalloz Ed; 2014. p. 179–84. Leroy P, Mamzer-Bruneel M-F, Hervé C, Scotté F. Une étude des conditions de recueil des consentements : quels enseignements ? In: Les nouveaux paradigmes de la médecine personnalisée ou médecine de précision. Paris: Dalloz Ed; 2014. p. 179–84.
27.
go back to reference Les nouveaux paradigmes de la médecine personnalisée ou médecine de précision. Dalloz Ed. Paris; 2014. Les nouveaux paradigmes de la médecine personnalisée ou médecine de précision. Dalloz Ed. Paris; 2014.
28.
go back to reference Les inégalités sociales et la santé. Dalloz Ed. Paris; 2015. Les inégalités sociales et la santé. Dalloz Ed. Paris; 2015.
29.
go back to reference Hoos A, Anderson J, Boutin M, Dewulf L, Geissler J, Johnston G, et al. Partnering with patients in the development and lifecycle of medicines. Ther Innov Regul Sci. 2015;49:929–39.CrossRefPubMedPubMedCentral Hoos A, Anderson J, Boutin M, Dewulf L, Geissler J, Johnston G, et al. Partnering with patients in the development and lifecycle of medicines. Ther Innov Regul Sci. 2015;49:929–39.CrossRefPubMedPubMedCentral
30.
32.
33.
Metadata
Title
Partnering with patients in translational oncology research: ethical approach
Authors
Marie-France Mamzer
Nathalie Duchange
Sylviane Darquy
Patrice Marvanne
Claude Rambaud
Giovanna Marsico
Catherine Cerisey
Florian Scotté
Anita Burgun
Cécile Badoual
Pierre Laurent-Puig
Christian Hervé
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2017
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-017-1177-9

Other articles of this Issue 1/2017

Journal of Translational Medicine 1/2017 Go to the issue